Compendium of Cancer Genome Aberrations

HAEM5:Primary cutaneous gamma/delta T-cell lymphoma: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
Line 8: Line 8:


==Primary Author(s)*==
==Primary Author(s)*==


Mahzad Azimpouran, MD; Sumire Kitahara, MD; Cedars-Sinai, Los Angeles, CA
Mahzad Azimpouran, MD; Sumire Kitahara, MD; Cedars-Sinai, Los Angeles, CA
Line 36: Line 35:


{| class="wikitable"
{| class="wikitable"
|+
|Acceptable
|Acceptable
|N/A
|N/A
Line 45: Line 43:


==Gene Rearrangements==
==Gene Rearrangements==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
 
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 138: Line 136:
|No
|No
|Amplification in ~39% of cases. Suggests MAPK/other pathway involvement but specific gene not yet defined.
|Amplification in ~39% of cases. Suggests MAPK/other pathway involvement but specific gene not yet defined.
|-
|Focal deletion: CDKN2A
|Loss (homozygous/biallelic)
|within 9p21.3, CDKN2A region
|CDKN2A
|P
|No
|From GISTIC analysis: CDKN2A deletion in 61% of samples,  45% biallelic.  Key focal region in PCGDTCL<ref name=":0" />
|-
|-
|Focal deletion: ARID1A
|Focal deletion: ARID1A
Retrieved from "https://test.ccga.io/index.php/HAEM5:Primary_cutaneous_gamma/delta_T-cell_lymphoma"